Background Identification of variable epidermal growth factor receptor (EGFR) gene
mutations in non-small cell lung cancer (NSCLC) is important for the selection of appropriate …

Abstract Treatment with 3 years of adjuvant osimertinib is considered a new standard in
patients with completely resected stage I to IIIA NSCLC harboring a common sensitizing …

Abstract On December 18, 2020, the FDA approved osimertinib as adjuvant therapy in
patients with non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are commonly used to
treat non-small cell lung cancers with EGFR mutations, but drug resistance often emerges …

Background Lung cancer remains a leading cause of cancer incidence and mortality
worldwide. Although Spain contributes to global statistics related to cancer, it is difficult to …

Background The third‐generation EGFR‐TKI, represented by osimertinib, has been widely
used in clinical practice; however, resistance eventually emerges. At present, it remains …

Background The resistance mechanism of the third generation of epidermal growth factor
(EGFR) tyrosine kinase inhibitor (TKI) osimertinib is complex. Epithelial mesenchymal …

Objectives The landmark ADAURA study recently demonstrated a significant disease-free
survival benefit of adjuvant osimertinib in patients with resected EGFR-mutated lung …

EGFR status assessment is mandatory for adjuvant decision-making of resected stage IB-IIIA
non-squamous non-small cell lung cancer (NS-NSCLC). It is questionable whether single …

Introduction Osimertinib is a central nervous system (CNS)-active, third generation,
irreversible, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that …